CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.

Abstract

The antiparkinsonian efficacy and tolerability of CQA 206-291, a novel ergoline derivative with potent dopamine agonist properties, were studied during 2 months of treatment in 72 parkinsonian patients. In 36 de novo patients (patients who have not previously been treated with levodopa or dopamine agonists), CQA 206-291 was studied in an open design, while in 36 levodopa-treated patients, CQA 206-291 was studied in a randomized, double-blind, parallel-group, placebo-controlled design. CQA 206-291 induced in both groups a significant antiparkinsonian effect with an effective dose range of 5-30 mg/day. The spectrum of adverse events was similar to what is commonly observed with dopamine agonists. Further studies are required to assess the putative therapeutic advantages of CQA 206-291 when compared to other antiparkinsonian drugs.

• Authors: O Rascol, N Fabre, H Teräväinen, W Poewe, C Lücking, U Rinne, E Dupont, D Hirt, M Hoyer, X Lataste
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) Vol. 13 Issue 4 Pg. 303-11 (Aug 1990) ISSN: 0362-5664 [Print] United States
• PMID: 2208182 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiparkinson Agents
• Ergolines
• Levodopa
• CQA 206-291

Topics

• Aged
• Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
• Drug Therapy, Combination
• Ergolines (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Levodopa (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Parkinson Disease (drug therapy)